Kymera Therapeutics stock heads toward key KT-621 data readout

Kymera Therapeutics is approaching a pivotal clinical milestone after the company said on October 29, 2026, that it plans to report topline data from its KT-621 BROADEN2 Phase 2b atopic dermatitis trial by year-end. The update was part of the company's third-quarter results and pipeline release, published by National Law Review.

KT-621 readout remains central

KT-621 is an oral STAT6 degrader being tested in Phase 2 studies for atopic dermatitis and asthma. Kymera said the last patient had completed the week 16 visit in BROADEN2 and that it expects to begin its first Phase 3 atopic dermatitis study by mid-2027, subject to regulatory discussions.

Enrollment remains under way in the BREADTH Phase 2b asthma trial, with topline data expected in late 2027. These milestones leave clinical execution and upcoming readouts as the main factors shaping the investment case.

KT-579 advances toward lupus

Kymera also reported positive results from the first-in-human KT-579 Phase 1 study in healthy volunteers. The company said the oral IRF5 degrader produced deep and sustained target degradation, including median degradation of at least 90 percent across several multiple-dose cohorts, while its safety profile was comparable to placebo.

The company plans to start the KT-579 LUMORA Phase 1b study in lupus patients by early 2027. The planned study is intended to assess biomarker effects and explore potential clinical benefits.

Spending rises with development work

Kymera reported a third-quarter net loss of 132.0 million US dollars, compared with 82.2 million US dollars a year earlier. Research and development expenses increased to 128.5 million US dollars from 74.1 million US dollars as the company invested in its STAT6 program, discovery platform and development organization.

Cash, cash equivalents and marketable securities totaled 1.646 billion US dollars at September 30, 2026. Kymera said this balance should fund operations into 2029 and beyond several clinical milestones.

Kymera's business and position

Kymera Therapeutics is a clinical-stage biotechnology company headquartered in Watertown, Massachusetts. It develops oral small-molecule medicines using targeted protein degradation to remove disease-causing proteins, with a focus on immunology and chronic inflammatory diseases. Its pipeline includes KT-621, KT-579 and partnered programs in immunology and oncology.

US equities remain sensitive to expectations for growth, interest rates and biotechnology funding conditions; follow the S&P 500 for the broader market setting.

More news and analyses on Kymera Therapeutics stock